Jazz Pharmaceuticals Posts Record $1.2B Quarter, Raises 2026 Outlook
Jazz Pharmaceuticals reported record quarterly revenues of $1.2 billion, up 10% year-over-year, and lifted its full-year 2026 revenue guidance.
Jazz Pharmaceuticals delivered its strongest quarterly revenue performance on record in the third quarter of 2026, with total revenues reaching $1.2 billion — a 10% increase compared with the same period a year earlier. The company attributed the results to broad commercial execution across its portfolio, prompting management to raise its full-year 2026 revenue guidance.
Xywav, the company's treatment for conditions including narcolepsy, was a notable driver of growth, with revenues climbing 12% year-over-year. The drug added 425 net patients during the quarter, signaling continued market penetration and steady physician adoption in its approved indications.
Read more Stark Future Raises €150M as Electric Dirt Bikes Outpace Gas Models →
Jazz also advanced its oncology pipeline during the period, launching Ziihera in the first-line metastatic gastroesophageal adenocarcinoma setting for patients with HER2-positive disease. The launch represents a commercial expansion into a competitive but high-need segment of the cancer treatment market.
The company further bolstered its pipeline and commercial prospects by closing the acquisition of Actio during the quarter. While specific financial terms of the deal were not detailed in the announcement, the transaction adds assets that could broaden Jazz's therapeutic reach beyond its existing franchises in sleep medicine and oncology.
The combination of organic revenue growth, a new product launch, a completed acquisition, and an upward revision to annual guidance positions Jazz as one of the more active mid-sized specialty pharmaceutical companies heading into the final stretch of fiscal 2026. Continue reading at Earnings.